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Ribosomes have been long considered as executors of the translational program. The
fact that ribosomes can control the translation of specific mRNAs or entire cellular
programs is often neglected. Ribosomopathies, inherited diseases with mutations in
ribosomal factors, show tissue specific defects and cancer predisposition. Studies
of ribosomopathies have paved the way to the concept that ribosomes may control
translation of specific mRNAs. Studies in Drosophila and mice support the existence
of heterogeneous ribosomes that differentially translate mRNAs to coordinate cellular
programs. Recent studies have now shown that ribosomal activity is not only a critical
regulator of growth but also of metabolism. For instance, glycolysis and mitochondrial
function have been found to be affected by ribosomal availability. Also, ATP levels drop in
models of ribosomopathies. We discuss findings highlighting the relevance of ribosome
heterogeneity in physiological and pathological conditions, as well as the possibility that
in rate-limiting situations, ribosomes may favor some translational programs. We discuss
the effects of ribosome heterogeneity on cellular metabolism, tumorigenesis and aging.
We speculate a scenario in which ribosomes are not only executors of a metabolic
program but act as modulators.
Keywords: ribosomal proteins, ribosomopathies, ribosome heterogeneity, metabolism, Shwachman-Diamond
syndrome, eIF6, RACK1
INTRODUCTION
Translation the process by which mRNAs are translated into proteins by ribosomes. Eukaryotic
ribosomes are evolutionarily conserved ribozymes constituted by ribosomal proteins (RPs) and
rRNAs, whose structure has been spectacularly resolved (Ben-Shem et al., 2011; Klinge et al., 2011;
Khatter et al., 2015). Ribosome biogenesis is a massive process occurring in the nucleolus of all
cells. Recent progress, combining biochemical techniques, with structural and genetic evidence,
has shown that ribosome synthesis is catalyzed and coordinated by more than 200 biogenesis
factors. Ribosome biogenesis, therefore, proceeds through precise assembly steps that include
several quality checkpoints, both in the nucleus and in the cytoplasm (Kressler et al., 2017; Pena
et al., 2017). Furthermore, impairment of these checkpoints leads to defects in maturation that are
associated with disease (Narla and Ebert, 2010; Ruggero and Shimamura, 2014).
In the cytoplasm, ribosomes are thought to constitute the hardware of the protein synthesis
machinery, which fulfills its activity through four main phases: initiation, elongation, termination,
and recycling. The initiation step is one of the most important steps of translation regulation,
involving initiation factors, mRNAs, tRNAs, and ribosomes. Briefly, 40S subunits directly bind
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mRNAs in a way that is dependent on initiation factors and
on mRNA structure and, after mRNA binding and scanning
to an appropriate start codon, 60S subunits are recruited.
Several studies elucidated how translation initiation is affected
by alteration in mRNAs-binding factors (Loreni et al., 2014;
Chu et al., 2016; Truitt and Ruggero, 2016) and by different
features in mRNAs structures, i.e., Untranslated regions (UTRs).
Recently, also tRNA has been linked to selective translation, and
reprogramming of metabolism since codon reprogramming leads
to HIF1α synthesis and an increase of glycolytic factors (Rapino
et al., 2018).
Evidences that ribosomes exist in different forms in different
cell types or during different stages of development (Milne
et al., 1975; Bortoluzzi et al., 2001; Volarevic and Thomas,
2001) have suggested the presence of ribosome heterogeneity.
It has been recently demonstrated that mutations in some
RPs result in selective translation (Shi and Barna, 2015)
and mutations in proteins causing an impairing in ribosome
maturation and function, as in the case of ribosomopathies,
show a specific mRNA translation signature (Brina et al.,
2015; In et al., 2016) In conclusion, in recent years there
has been growing evidence that translation is driven by
ribosome heterogeneity, manifested as ribosome populations
differing in ribosomal components. In this review we discuss
ribosome heterogeneity in physiological, and pathological
conditions, highlighting the role of translation machinery
in driving the last step of the molecular biology central
dogma, which elects ribosomes as players in specific mRNAs
translation.
Ribosome Heterogeneity in Physiological
Conditions May Account for Differential
Translation
This topic has been recently discussed (Genuth and Barna,
2018a,b) and we will give a simple summary of some perspectives.
Ribosomes are constituted by approximately 80 RPs. For
many years now, it is known that the relative abundance
of different RPs, in different tissues, or in different growth
conditions, may vary (Milne et al., 1975; Bortoluzzi et al.,
2001; Volarevic and Thomas, 2001). This is a sine qua non-
condition for ribosomal heterogeneity. An obvious alternative
explanation for an imbalance of the stoichiometry of RPs within
a cell is that RPs perform ribosome-independent functions.
An experimental complexity is, therefore, to define whether a
differential translation is due to the direct action of heterogeneous
ribosomes or to regulatory pathways affected by free RPs. This
is the case for RACK1 that was originally isolated as a PKC
receptor (Ron et al., 1994; Gallo and Manfrini, 2015). RACK1
is a structural protein of 40S subunits (Gerbasi et al., 2004),
involved in several extraribosomal functions (Mamidipudi et al.,
2004; Robles et al., 2010; Wehner et al., 2011; Gandin et al.,
2013; Fei et al., 2017). RACK1 may affect the efficiency of
ribosomes directly (Ceci et al., 2003; Shor et al., 2003; Guo
J. et al., 2011; Dobrikov et al., 2018a,b) or indirectly through
signaling pathways (Gandin et al., 2013; Volta et al., 2013). In
conclusion, data demonstrate that in physiological conditions,
ribosomal networks may be more complex than expected and
perform choices in translational regulation.
Ribosomal heterogeneity exists in physiological conditions.
Accurate proteomics studies have identified sub-stoichiometric
relationships within translating polysomes (Shi et al., 2017),
showing that ribosomes may preferentially translate specific
mRNAs. An experimental validation shows that ribosomes
devoid of either RPS25 (eS25) or RpL10A (uL1), in vivo, translate
specific mRNAs. Mechanistically, this study shows that the 60S
subunits may affect mRNA recruitment through the binding of
RPL10A (uL1) to IRES (Internal Ribosome Entry Site) sequences
in the 5′UTR (Shi et al., 2017). In monocytes, interferon gamma
driven phosphorylation results in RPL13A (uL13) detachment,
but here it is still unknown whether ribosomes devoid of
RPL13A (uL13) are able to translate selectively (Jia et al., 2012).
Furthermore, RPL10 (uL16) R98S mutant leukemia cells are
able to survive high oxidative stress levels by increasing IRES-
dependent BCL-2 translation (Kampen et al., 2018).
Thus, the concept of a monolithic ribosome (Moore et al.,
1968; Yusupova and Yusupov, 2017) may be accompanied by
the existence of a more flexible ribosomal platform that performs
further tuning on gene expression (Shi and Barna, 2015).
Ribosome Heterogeneity in Pathological
Conditions Affects Translation and Gene
Expression
Ribosomopathies are inherited diseases caused by the loss
of ribosomal component functionality. Some examples
of ribosomopathies include Diamond-Blackfan Anemia
syndrome (DBA), Shwachman-Diamond syndrome (SDS),
Treacher Collins syndrome, 5q-myelodysplastic syndrome, and
Dyskeratosis Congenita (DKC). Notably, all of these syndromes
are characterized by variably penetrant phenotypes in which
specific tissue deficits are found (Narla and Ebert, 2010). Early
on, it was shown that DKC1 mutations reduce pseudouridylation
and impair IRES mediated translation (Yoon et al., 2006).
As a case for study, we will focus our discussion on SDS. Signs
of SDS include a peculiar exocrine pancreatic insufficiency, along
with neutropenia and variable abnormalities in the skeleton and
other organs. In addition, SDS is characterized by a reduction
in growth, accompanied by an increased incidence of Acute
Myeloid Leukemia, (AML; Dror, 2008). At the ribosomal level,
SDS is characterized by the partial loss of free 60S ribosomal
subunits due to, in most cases, mutations in the SBDS gene that is
necessary for 60S maturation (Boocock et al., 2003; Wong et al.,
2011). In a minority of cases, mutations of EFL1p, which acts in
synergy with SBDS, have been found (Stepensky et al., 2017; Tan
et al., 2018). Overall, the reduced functionality of 60S ribosomes
is a common theme for SDS (Warren, 2018). All together these
findings generate three questions: (a) how the loss of functionality
of ubiquitous 60S ribosomes can generate tissue-specific defects,
(b) how specific translational programs can be affected by the lack
of 60S subunits, (c) how can we reconcile increased tumor with
reduced growth.
Addressing this last question helps to put in the right context
the other two. We have recently demonstrated in our lab that
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cells with mutant Sbds have reduced colony formation ability
and are transformed less efficiently by oncogenes (Calamita et al.,
2017). In this context, we demonstrated that Sbds deficiency
directly acts by reducing the maximal oncogenic and translational
capability of cells (Calamita et al., 2017). The paradox of reduced
growth associated with tumor predisposition may not necessarily
be associated with specific translation in tumor cells, but with
a general impairment of tissue homeostasis that favors the
appearance of mutant clones. For instance, increased tumor
formation is observed in immunocompromised individuals
(Verhoeven et al., 2018). To support this interpretation, the
relationship between neutropenia and AML was described by
different groups (Freedman et al., 2000; Link et al., 2007; Touw
and Beekman, 2013). In conclusion, different cell types can be
differentially affected by the reduction of RPs, i.e., thresholds
can be different depending on the specific cellular demand of
ribosomes for translation.
The question of the mechanism by which defects in 60S
ribosomes lead to differential translation is more challenging
since to our knowledge mRNA selection is driven by 40S
subunits, prior to 60S engagement. However, the effects of 60S
levels on specific translation are pervasive, and, as described
before, IRES mRNA binding can be affected by RPL10 (uL16).
In the case of Sbds depletion, characterized by reduced free
60S, two studies have addressed the question of preferential
translation performing either microarray (Nihrane et al., 2009),
or RNA-Seq on polysomes (Calamita et al., 2017). In addition,
a reporter-based study has addressed the effect of SBDS
depletion on reinitiation (In et al., 2016). Together, these studies
support a model in which the SBDS deficiency reduces free
60S levels diminishing the maximal translational capability,
and simultaneously changing translational selectivity. In this
context, mRNAs that are intrinsically poorly translated because
of uORFs (upstream Open Reading Frames) that require
reinitiation are particularly disfavored. Similarly, mouse models
have underscored that the reduction of 60S RPs affects the
translational program of IRES containing mRNAs (Barna et al.,
2008; Kondrashov et al., 2011; Xue et al., 2015).
Finally, mathematical modeling of translation suggests that a
quantitative reduction in the translational output may result in
strong alterations of specific mRNA translation due to stochastic
events (Heinrich and Rapoport, 1980; Mills and Green, 2017).
We conclude that some mRNAs can be particularly sensitive to
ribosomal availability, and we speculate that this property has
been evolutionarily exploited to connect ribosomes with other
cellular events. What we still lack is understanding the precise
mechanisms.
A Common Theme for the Regulatory
Function of Ribosomes?
Metabolic pathways are necessary for converting essential
nutrients into energy and macromolecules that sustain cell
growth and proliferation. Nutrients and metabolic pathways
control all facets of cellular functions. Nutrient and growth
factors converge on the translational machinery through
signaling pathways that, in turn, regulate the synthesis of
ribosomes and the activity of translation factors (Roux and
Topisirovic, 2018). Then, translation factors crosstalk to
metabolic choices (Biffo et al., 2018). Some well-established
observations are the following. mTORC1 controls mitochondrial
activity and biogenesis by selectively promoting translation of
nucleus-encoded mitochondria-related mRNAs, via inhibition of
the eukaryotic translation initiation factor 4E (eIF4E)-binding
proteins (4E-BPs; Morita et al., 2013). ROS generation is
also controlled partly at the translational level through eIF4E
(Truitt et al., 2015). Glutamine metabolism is controlled by
eIF4B-mediated translation downstream of mTORC1 pathway
(Csibi et al., 2014). eIF3 complex mediates energy metabolism
(Shah et al., 2016). Rate-limiting initiation factors that link
60S ribosome biogenesis to translation as eIF6 hierarchically
control lipid synthesis and metabolism, through uORF and G/C
rich 5′UTR sequences (Brina et al., 2015). eIF5A2 accelerates
lipogenesis in hepatocellular carcinoma (Cao et al., 2017).
In general, translation and metabolism are dysregulated in a
coordinated fashion (Leibovitch and Topisirovic, 2018), and
initiation factors may act upstream of metabolic reprogramming
(Biffo et al., 2018). The next question is whether ribosomes also
control metabolic pathways.
In Zebrafish, rpl11 mutation decreased the glycolytic rate
and the lower activity of glycolytic enzymes is rescued by p53
inhibition (Danilova et al., 2011). Moreover, defects, mutations
or imbalance of RPs stabilized p53 and changed metabolic
flux, specifically by decreasing glycolysis and enhancing aerobic
respiration (Deisenroth and Zhang, 2011). Albeit these data
FIGURE 1 | Heat map representing relative gene expression levels in a cellular
model for Shwachman Diamond Syndrome. We re-infected cells bearing the
mutation R126T/R126T (corresponding to one of the most common
mutations associated with Shwachman Diamond Syndrome) in the Sbds gene
(SbdsR126T/R126T MEFs) with either wild type Sbds (SbdsRESCUE ), or mock
control (SbdsMOCK ). Heat map represents relative gene expression levels of
genes associated with mitochondrial electron transport chain complex IV,
showing an overall reduction in mutant SbdsMOCK cells, indicating an
impairment in ATP production. Heatmap is based on RNASeq raw data
available at www.ebi.ac.uk/arrayexpress with accession number ID
E-MTAB-5089, and analyzed in our previous work (Calamita et al., 2017).
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do not support a direct crosstalk between ribosome activity
and metabolism, they suggest overall that when the translation
machinery is perturbed, coordinated pathways involved in cell
homeostasis and metabolism are also altered.
Recently, it has been shown that SDS cells display an
impairment in Complex IV activity, which causes an oxidative
phosphorylation metabolic defect, with a consequent decrease in
ATP production (Ravera et al., 2016). The authors suggest an
indirect effect of SBDS mutation on energy production levels,
indicating a possible role of calcium homeostasis in altering
complex IV activity. In our lab we performed a characterization
of a cellular model for SDS by immortalizing Mouse Embryonic
Fibroblasts (MEFs; Calamita et al., 2017) derived from an SDS
mouse model carrying the R126T mutation in homozygosity
(SbdsR126T/R126T MEFs) (Tourlakis et al., 2012). Briefly, we
established a model for studying SBDS function by retrasducing
SbdsR126T/R126T MEFs with either wild-type Sbds (SbdsRESCUE),
or mock control (SbdsMOCK) vectors. In this way, we can
separate direct events due to a lack of SBDS from indirect
effects. We confirmed a decrease in ATP levels associated with
Sbds mutation. In addition, our RNA-Seq analysis revealed that
genes belonging to complex IV were less expressed when Sbds
was mutated (Figure 1). This downregulation could explain an
impairment in cytochrome C oxidase activity and a consequent
defect in ATP production. Moreover, there is a defect in oxygen
consumption rate in SDS cells (Ravera et al., 2016; Calamita
et al., 2017), as well as a reduction in the lactate/pyruvate ratio
(Calamita et al., 2017). The mechanistic connection between
ribosome function and the metabolic effects of its impairment is
still to be clarified. Overall, a reduction in ribosomal efficiency
seems to associate with a reduction in energy levels and lipid
biosynthesis. We suggest that ribosomal capability has coevolved
with other cellular functions and, specifically, ribosomes are
intimately linked to nutrient levels and cellular growth.
The connection between ribosomes and growth is indeed
strong and well-known. In Drosophila melanogaster the
haploinsufficiency of RPs results in the minute phenotype, which
includes short and thin bristles and smaller flies (Lambertsson,
1998; Marygold et al., 2007). Moreover, as shown by a myriad
of papers, depletion of RPs causes a delay/arrest in cell cycle
progression. In several cases, the regulation of growth is
associated with ribosome independent function of RPs (Dai and
Lu, 2004; Mamidipudi et al., 2004, Dutt et al., 2011; Yao et al.,
2016). In other cases, the inhibition of growth has been directly
FIGURE 2 | A schematic model representing the list of genes whose mutations perturb ribosome machinery. The color indicates the associated phenotype, specified
in ovals in the third row. In some cases, the effect is associated or supposed to be associated with extra-ribosomal functions of mutated genes (listed in squares in
the fourth row). Briefly, alterations in ribosome biogenesis and/or mutations in ribosomal proteins are responsible for metabolic changes, abnormal cell cycle
progression/cell growth, and selective translation. Ribosomal subunits adapted from 40S (Lomakin and Steitz, 2013) PDB code 5ANB to 60S (Weis et al., 2015)
PDB code 4KZX. Orange color indicates the flux of alterations converging to metabolic defects, green color the flux converging to selective translation and blue color
the one converging to altered cell cycle/cell growth. The exploration of effects of RP lesions on cell cycle, translation, and cell metabolism is a highly active area of
research and novel effects of RP lesions still need to be discovered. 1Danilova et al., 2011; 2Calamita et al., 2017; 3Angrisani et al., 2018; 4Ravera et al., 2016; 5Shi
et al., 2017; 6 In et al., 2016; 7Miller et al., 2004; 8Yoon et al., 2011; 9Li et al., 2016; 10Ceci et al., 2012; 11Menne et al., 2007; 12Volarevic et al., 2000; 13Sulic et al.,
2005; 14Dutt et al., 2011; 15Teng et al., 2013; 16Hermanto et al., 2002; 17Mamidipudi et al., 2004; 18Fei et al., 2017; 19Alawi and Lin, 2013; 20Ge et al., 2010; 21Yao
et al., 2016; 22Badhai et al., 2009; 23He et al., 2016; 24Dai et al., 2004; 25Yoon et al., 2006; 26Li et al., 2012; 27Stadanlick et al., 2011; 28Kampen et al., 2018; 29De
Keersmaecker et al., 2013.
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linked to translational control driven by ribosomes (Barna et al.,
2008). Depletion of different RPs may result in different types
of inhibition of cell cycle progression, in line with the concept
of heterogeneity in ribosomes (Badhai et al., 2009). Conversely,
nucleolar enlargement grossly equals an increased production of
ribosomes and is observed in many cancers (Montanaro et al.,
2008). In many models, some heterozygous deletions of RPs
reduce tumor growth (Barna et al., 2008; Chen et al., 2014;
Wilson-Edell et al., 2014), while some others are associated
with cancer development as demonstrated for the first time in
zebrafish mutants for RPs in 2004 (Amsterdam et al., 2004).
In the last years, several somatic mutations have been linked
to tumor progression and belong to both 60S subunits such as
RPL5 (uL18) and RPL10 (uL16) (De Keersmaecker et al., 2013),
RPL 11 (uL5) (Tzoneva et al., 2013; Fancello et al., 2017), RPL22
(eL22) (Rao et al., 2012) and RPL 23 (uL23) (Fancello et al., 2017)
and to 40S subunits such as RPS15 (uS19) (Landau et al., 2015;
Ljungstrom et al., 2016), RPS27 (eS27) (Dutton-Regester et al.,
2014) and RPSA (uS2) (Fancello et al., 2017). On the contrary,
RPs overexpression has been also identified in cancer progression
(Artero-Castro et al., 2011; Guo X. et al., 2011; Yang et al., 2016).
Several recent reviews provide a comprehensive discussion on
how, in some cases, loss of RPs contributes to cancer (Sulima
et al., 2017; Genuth and Barna, 2018a; Pelletier et al., 2018).
The ribosomal apparatus also appears to affect longevity.
Alterations in ribosomal protein expression result in an extension
of eukaryotic lifespan (Hansen et al., 2007; Steffen et al., 2008).
In short, the persistent link between ribosomal function in
growth and metabolism makes us speculate that there may be
a yet-to-be-unveiled mechanistic connection. We favor a model
in which mRNAs important for cell cycle progression or for key
metabolic pathways contain UTRs that have coevolved with the
translational machinery in order to be preferentially translated
in conditions of optimal ribosomal capability. In this context,
ribosomal heterogeneity may further tune the cell′s translational
capabilities.
Mitochondrial Ribosomes
Several mitochondrial ribosome proteins are also involved
in different cellular processes, such as cell cycle, apoptosis
and mitochondrial homeostasis regulation. Mutations in mt-
RPs genes are associated with mitochondrial dysfunctions and
disorders (Saada et al., 2007; Smits et al., 2011; Serre et al.,
2013; Menezes et al., 2015; Richman et al., 2015). For instance,
mutant MRPS16 (bS16m) causes mitochondrial respiratory chain
disorders (Miller et al., 2004) and loss of MRPL10 (uL10m)
diminished mitochondrial respiration and intracellular ATP
levels (Li et al., 2016). In addition, a recent study claims the
regulation of cytoplasmic protein homeostasis by mitochondrial
translation (Suhm et al., 2018). These studies elucidate the fact
that a crosstalk between the cytoplasmic and the mitochondrial
ribosomal machinery may be present.
CONCLUSION
Ribosomes have been long considered as monolithic structures
ensuring mRNAs translation in a passive way. Nowadays, it
has been well established that ribosomes can affect not only
mRNA selection but also other fundamental processes such as cell
growth and lately, cell homeostasis and metabolism (Figure 2).
There is an increasing number of studies evidencing that the
inter-correlation between ribosomes and metabolic pathways
leads to a common cellular phenotype. Since ribosomes are a
rate-limiting component of the translational program, further
studies are needed to elucidate specific molecular mechanisms
by which ribosome heterogeneity, supported by the translational
apparatus, sustain cell growth and metabolic homeostasis.
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